Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

May 08, 2007; 68 (19) Articles

Implications of ALS focality

Rostral–caudal distribution of lower motor neuron loss postmortem

John Ravits, Patrick Laurie, Yuxin Fan, Dan H. Moore
First published May 7, 2007, DOI: https://doi.org/10.1212/01.wnl.0000261045.57095.56
John Ravits
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Laurie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuxin Fan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dan H. Moore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Implications of ALS focality
Rostral–caudal distribution of lower motor neuron loss postmortem
John Ravits, Patrick Laurie, Yuxin Fan, Dan H. Moore
Neurology May 2007, 68 (19) 1576-1582; DOI: 10.1212/01.wnl.0000261045.57095.56

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
544

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Background: Because motor manifestations of ALS begin focally and progress contiguously, the anatomic distribution of underlying lower motor neuron and upper motor neuron degeneration should correlate to onset.

Objectives: To assess the rostral–caudal distribution of lower motor neuron loss in relation to the region of clinical onset.

Methods: We evaluated 19 ALS postmortem nervous systems from patients whose motor manifestations had begun in different body regions. In each, we looked at four neuraxis levels: hypoglossal nucleus and cervical, thoracic, and lumbar spinal cord. We used light microscopy and devised a technique of particle counting that indexed lower motor neuron loss.

Results: The average overall loss of lower motor neurons in ALS nervous systems was 55%, and the range of loss had a normal distribution that ranged between 8% and 90%. The distribution of lower motor neuron loss was graded within the nervous system relative to onset (p = 0.02 by analysis of variance). In 14 of the 19 nervous systems, the regional lower motor neuron loss within the nervous systems was graded radially away from the region of onset. In 1, radial degeneration seemed likely but did not meet significance. In 2, radial degeneration was apparent but loss was greatest in a region different than that identified as the region of onset. In the remaining 2, lower motor neuron loss was minimal and not graded (both from patients whose motor manifestations had been predominantly upper motor neuron).

Conclusion: Lower motor neuron degeneration in ALS is a focal process that advances contiguously, summates over time, and creates graded loss. Stage of degeneration in the nervous system is a function of anatomic location.

Motor manifestations of ALS begin focally and progress contiguously outward.1–3 Because they are caused by simultaneous degeneration of upper motor neurons (UMNs) and lower motor neurons (LMNs), throughout the course of the disease including at the time of death, there should be a relationship between clinical onset and distribution of motor neuron loss—for LMNs, a rostral–caudal gradation; for UMNs, a lateral–medial gradation. It is difficult if even possible to do this for UMNs because of difficulties with identification, localization, standardization, and quantification.4–8 But it is feasible to do this for LMNs because they are distinctly located in motor columns, readily identified, obviously correlated with body regions, and well characterized morphometrically. We therefore did so for LMN loss in a sample of nervous systems from patients whose disease had begun in different body regions. We found that LMN loss was usually radial—greatest at the region of onset and decreased outward. This supports the idea that ALS motor neuron degeneration is a focal process that advances contiguously and summates over time and suggests that stage of degeneration in the nervous system is relative to anatomic location.

METHODS

Selection and demographics.

We evaluated 19 ALS and 8 control nervous systems from our ALS tissue repository. Inclusion criteria for the ALS nervous systems were as follows: nervous systems came from patients who had met modified El Escorial criteria for definite ALS9; disease was sporadic; disease had no atypical clinical or neuropathologic features; disease onset was from representative regions of the body (bulbar, arm, trunk, and leg); and histology was available for all four neuraxis levels—medulla, cervical, thoracic, and lumbar regions. Demographics are shown in table 1. In the ALS group, nervous systems were from 12 men and 7 women; the mean age was 67 years (range 41 to 84 years). In the control group, nervous systems were from 7 men and 1 women; the mean age was 63 years (range 38 to 80 years). Postmortem intervals averaged 5.25 hours (range 2.0 to 12 hours). All nervous systems had been acquired with an Investigational Review Board and Health Insurance Portability and Accountability Act–compliant informed consent process.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 1 Demographics

Histologic sampling.

We used 6-μm-thick sections from formalin-fixed, paraffin-embedded tissues stained with cresyl violet acetate. We studied four neuraxis levels: hypoglossal nucleus at the midmedulla, midcervical spinal enlargement, midthoracic spinal region, and midlumbar spinal enlargement. We standardized rostral–caudal sampling of the hypoglossal nucleus by its relation to the medial longitudinal fasciculus and by the morphology of the fourth ventricle.10 We standardized rostral–caudal sampling of spinal cord regions by choosing middle segments—the cervical region has uniform counts between C4 and C8,11,12 the lumbar region has uniform neuron counts between L3 and S2,13–15 and we assume the midthoracic region has uniform counts. Because motor neuron presence varies from one histologic section to another,11,15–17 we evaluated a total of eight sections from each neuraxis level, choosing every 10th section for a sampling interval of 60 μm from a series of 84 consecutive sections spanning 504 μm, a sampling technique modified from Method 1 of Tomlinson et al.16 We separately imaged each side of the spinal anterior horns and hypoglossal nucleus under 50× with a Leica DM2500 microscope with a Spot Insight 4 digital camera and Spot Advanced version 4.5.7 software (Diagnostic Instruments, Inc., Sterling Heights, MI) and stored each image in Tagged-Image File Format.

Counting.

To meet the realities of the counting task, we devised a method of counting neuron “particles” to index relative neuron presence rather than determining absolute neuron counts18—stereology technologies do not apply to the motor neurons19 and automated particle counting software was inefficient, experience reported by others.20 Our method had three observers (J.R., P.L., and Y.F.) independently count motor neuron particles in each image file according to the following criteria learned in training sessions to standardize counting: neurons were located in the anterior portion of the anterior horns of the spinal cord segments or in the hypoglossal,10 had relatively deep Nissl staining, were generally multiconcave, and were larger than 25 μm in diameter in cervical and lumbar regions and larger than 15 to 20 μm in thoracic and hypoglossal regions. Both sides were counted. We were careful to avoid counting neurons in the perihypoglossal nuclei, the intermediolateral cell column, and Clarke's column. Because there is no significant shrinkage of motor neurons in ALS vs controls,20–22 we did not correct for split cell error.23,24

Blinding and controls.

Observers were blind to sample identification, although in many cases, ALS nervous systems were identified by the obvious motor neuron loss; in such cases, the site of clinical onset was not known and not obvious. Control nervous systems were age-matched with the ALS nervous systems, although in our controls, contrary to other reports,14,25,26 age-related changes were not pronounced.

Statistics and calculations.

We compiled particle counts in a spreadsheet and then transferred them to the statistical package Stata (version 9.2) (StataCorp LP, College Station, TX) for statistical analysis by multiway analysis of variance (ANOVA). To normalize variation across observers and across neuraxis levels, we transformed counts to percentages of control values. To do this, we expressed each observer's mean count per level for each ALS nervous system as a percentage of that observer's mean count for that level in controls, thus indexing observers to themselves. We then averaged these percentages across observers for subsequent calculations and ANOVA. Neuron loss was expressed as percent and calculated as 100 counts. Overall neuron counts and neuron loss were calculated as an even-weighted average of the four neuraxis levels and did not adjust for their different lengths or neuron densities because we were interested in relative changes along the rostral–caudal span.

RESULTS

The particle counts for each nervous system are shown in table 2 and are displayed graphically arranged by age in figure E-1 on the Neurology Web site at www.neurology.org. The calculated overall loss of LMNs in the ALS nervous systems averaged 55%, was normally distributed, and ranged between 8% and 90% (figure 1). In general, nervous systems from younger aged patients had greater degrees of loss (figure E-1). The distribution of LMN loss was usually graded within the nervous system (p = 0.02 by ANOVA; figure 2). In 14 of the 19 ALS nervous systems, loss was greatest at the neuraxis level that corresponded to the region of onset—4 of 6 nervous systems from patients with bulbar onset, 7 of 7 nervous systems from patients with arm onset, 3 of 3 nervous systems from patients with truncal onset, and 0 of 3 nervous systems from patients with leg onset. In 1 nervous system (No. 29), radial degeneration was apparent but did not meet statistical significance. In 2 nervous systems (Nos. 6 and 41), radial degeneration was apparent but loss was greatest in a region different from that identified as the region of onset, suggesting possible misappropriation. In 2 nervous systems (Nos. 34 and 36), LMN loss was minimal and radial degeneration was not seen—both were from patients who had had predominant UMN signs clinically. In all nervous systems, LMN loss averaged 68% in the region of clinical onset and 44% in remoter regions. In nervous systems from onset at the anatomic extremes, bulbar and leg onset patients, LMN loss averaged 54% in the region of onset and 22% in the remotest region. The composite data for each region of onset are presented in table 3 and also show this gradation except in the nervous systems from leg onset patients, where 1 of the 3 seemed misappropriated and 1 other had predominantly UMN involvement.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 2 LMN particle counts

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1 Frequency histogram of distribution of overall LMN loss in each ALS nervous system

The total overall LMN loss calculated for each nervous system from the four neuraxis regions (hypoglossal nucleus, cervical anterior horn, thoracic anterior horn, and lumbar anterior horn) is highly variable and normally distributed. LMN = lower motor neuron.

Figure2
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 2 Rostral–caudal distribution of motor neuron degeneration by region of onset

Focal onset and contiguous advancement of motor neuron degeneration frequently creates radial degeneration, the greatest neuronal loss in the region of onset, and progressively less loss in remoter regions. All images are consistently arranged anterior up and right side to the right. The densely staining cells standing out from the background are motor neurons. From the top, patients are 7, 14, 16, 21, and 29. (Cresyl violet acetate; 100×; scale bar is 100 μm.)

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 3 Composite counts

DISCUSSION

The neuropathologic hallmark of ALS is degeneration and loss of motor neurons.27 While the stages of degeneration leading to loss are chromatolysis, somatodendritic attrition, and apoptosis,28,29 in fact they are not conspicuous and there is generally remarkably little to be seen of a spectrum of morphologic change. Most neuropathologic evaluations have been of LMNs—LMNs are stacked in columns that are arranged rostral to caudal in motor nuclei in the tegmentum of the brainstem for bulbar muscles10,30 and in the anterior horns of the spinal cord for limb muscles.11,13–15,30–33 In spinal anterior horns, three distinct populations of neurons exist: large alpha motor neurons, which have 35- to 100-μm diameters and are located in the anterior portions of the horn; intermediate-sized gamma motor neurons, which have 25- to 35-μm diameters and are distributed among the alpha motor neurons; and small neurons such as interneurons, which have diameters less than 25 μm and are located dorsally and medially in the horn.14,15,34,35

Several morphometric studies have quantified LMN degeneration in ALS at specific regions of the spinal cord—C6,17 C8,36 L3,20 L4,22 and L5.21 Nearly all of the morphometric studies of LMNs have demonstrated significant decreases in the numbers but not diameter sizes of the neurons and little or no dispersion or shift from large to smaller sizes, showing that neuronal atrophy does not occur or is inconspicuous.20–22 Only one study reported a decrease of neuronal area,5 and the explanation for its disparity with the other studies may be that degeneration affects neuron shape.37 All three populations of neurons in the anterior horns, small neurons, and alpha and gamma motor neurons are affected in ALS.20,22,38,39 Neuronal loss may be patchy, focal, and asymmetric and does not seem to affect particular motor cells or columns of cells more than others.36 Not explicitly addressed in any of these morphometric studies but apparent in the data are variability of the degree of neuronal loss—we calculate from the published data that in these studies the average loss of large motor neurons ranged from 51% to 94% and that within each study individual nervous system loss of large sized motor neurons ranged from 23% to 100%.17,20–22,36

Because of the focally progressive nature of motor deficits during the clinical course of the disease,3 underlying motor neuron degeneration should be a focally progressive process and lead to a relatively orderly summation and distribution of loss in the neuraxis. This has not been specifically analyzed, and we therefore pursued this in the LMN compartment. We found that indeed this was the case: LMN loss correlated well with the region of onset and degeneration was radially graded—greatest in the region of onset and decreased away. The true extent of the radial degeneration likely is greater than indicated by our counts. Our counting method was designed to compare between regions of the same nervous system and also to compare between regions of different nervous systems, and to do this in the presence of the marked variability of normal and pathologic anatomy, the true gradation was likely underrated.

Because degeneration advanced outward from the region of onset, summating LMNs loss in the fixed and finite neuronal population sometimes so reduced the numbers that radial gradation became unapparent—in these nervous systems, radial change was often observed in more remote regions. When LMN degeneration began in or near regions controlling respiratory function, death occurred early in the course of degeneration, and there was relatively little overall LMN loss. This is a unique feature of ALS—death occurs during the course of motor neuron degeneration rather than at the end of the degenerative process,40–42 which continues if respiratory function is supported,43 and contrasts with other neurodegenerative diseases, where death almost always occurs after underlying neuropathologic degeneration is essentially completed.

In two nervous systems, LMN loss was minimal and not obviously radially graded. These were from patients who had had predominantly UMN involvement during the clinical phase of the disease and therefore neuropathologic burden at the UMN level. This highlights that both UMN and LMN degeneration are simultaneous and independent at the two levels of the motor system5,6 and that either one alone is sufficient for progressive deterioration. UMNs are spread in laminar sheets that are arranged somatotopically lateral to medial in layer V of the motor cortex.4 They are a heterogeneous population of medium to large pyramidal-shaped neurons, and their most prominent components are the Betz cells, distinguished chiefly by their giant size.4,44–46 Morphometry of the UMN is more difficult than for LMN, but a few studies have been performed,5–8 two of which were not able to demonstrate neuron loss at the motor cortex at all, presumably because of technical aspects of the new stereology techniques.7,8 Morphometry demonstrating a possible lateral-to-medial gradation of neuron loss along the somatotopically organized motor gyri analogous to what we demonstrated for the LMN is difficult if even possible: the oblique orientation of the motor cortex defies traditional coronal sectioning; identification of the motor cortex may be difficult or uncertain in ALS because its chief distinguishing feature, the Betz cell, is or may be reduced or absent; somatotopic localization of body regions is not distinct by histology; the medial to lateral arrangement of sizes and densities of Betz cells along the gyrus is complex; and differentiation of UMNs from other pyramidal neurons in layer V is technically problematic.4,6–8,18

That motor neuron degeneration is a focal and contiguously advancing process that summates over time both within and between the LMN and UMN compartments in the three dimensions of the motor system explains the well-ordered but highly varied LMN loss that occurs both within and between different nervous systems, averaging 55% with a normal distribution between minimal and severe. This creates stages of motor neuron degeneration that in turn could be exploited by new genomic technologies that key directly on relevant neuronal and glial compartments to explore molecular mechanisms of degeneration in ways greater now than previously possible.47–52

Footnotes

  • See also page 1571

    Supplemental data at www.neurology.org

    Supported by grants from the National Institute of Neurological Diseases and Stroke (NS051738), Juniper Foundation, Moyer Foundation, and Benaroya Foundation.

    Disclosure: The authors report no conflicts of interest.

    Presented in part at the 58th Annual Meeting of the American Academy of Neurology, San Diego, CA, April 1–8, 2006.

    Received December 21, 2005. Accepted in final form January 30, 2007.

REFERENCES

  1. 1.↵
    Gowers WR. Manual of diseases of the nervous system. London: Churchill, 1886–1888 (reprinted special edition, Birmingham, AL: Classics of Medicine Library, 1981).
  2. 2.
    Brooks BR. The role of axonal transport in neurodegenerative disease spread: a meta-analysis of experimental and clinical poliomyelitis compares with amyotrophic lateral sclerosis. Can J Neurol Sci 1991;18:435–438.
    OpenUrlPubMed
  3. 3.↵
    Ravits J, Paul P, Jorg C. Focality of upper and lower motor neuron degeneration at the clinical onset of ALS. Neurology 2007;68:1571–1575.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    Rivara CB, Sherwood CC, Bouras C, et al. Stereological characterization and spatial distribution patterns of Betz cells in the human primary motor cortex. Anat Rec 2003;270A:137–151.
    OpenUrlPubMed
  5. 5.↵
    Kiernan JA, Hudson AJ. Changes in sizes of cortical and lower motor neurons in amyotrophic lateral sclerosis. Brain 1991;114:843–853.
    OpenUrlAbstract/FREE Full Text
  6. 6.
    Pamphlett R, Kril J, Hng TM. Motor neuron disease: a primary disorder of corticomotor neurons? Muscle Nerve 1995;18:314–318.
    OpenUrlCrossRefPubMed
  7. 7.↵
    Gredal O, Pakkenberg H, Karlsborg, et al. Unchanged total number of neurons in motor cortex and neocortex in amyotrophic lateral sclerosis: a stereological study. J Neurosci Meth 2000;95:171–176.
    OpenUrlCrossRefPubMed
  8. 8.
    Toft MH, Gredal O, Pakkenberg B. The size distribution of neurons in the motor cortex in amyotrophic lateral sclerosis. J Anat 2005;207:399–407.
    OpenUrlCrossRefPubMed
  9. 9.↵
    Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293–299.
    OpenUrlCrossRefPubMed
  10. 10.↵
    Olszewski J, Baxter D. Cytoarchitecture of the human brain stem. 2nd ed. Basel: S. Karger, 1982:26–38 (Plates VIII–XX), 62–63.
  11. 11.↵
    Elliott HC. Studies on the motor cells of the spinal cord: I. Distribution in the normal human cord Am J Anat 1942;70:95–117.
    OpenUrlCrossRef
  12. 12.
    Yuan H, Ke M, Goto N, et al. Morphometric evaluation of the human cervical motoneurons. Okajimas Folia Anat Jpn 2000;76:277–284.
    OpenUrlPubMed
  13. 13.↵
    Irving D, Rebeiz JJ, Tomlinson BE. The numbers of limb motor neurones in the individual segments of the human lumbosacral spinal cord. J Neurol Sci 1974;21:203–212.
    OpenUrlPubMed
  14. 14.↵
    Kawamura Y, O'Brien P, Okazaki H, Dyck PJ. Lumbar motoneurons of man II: the number and diameter distribution of large- and intermediate-diameter cytons in “motoneuron columns” of spinal cord of man. J Neuropathol Exp Neurol 1977;36:861–870.
    OpenUrlPubMed
  15. 15.
    Kawamura Y, Dyck PJ. Lumbar motoneurons of man: III. The number and diameter distribution of large- and intermediate-diameter cytons by nuclear columns. J Neuropathol Exp Neurol 1977;36:956–963.
    OpenUrlPubMed
  16. 16.↵
    Tomlinson BE, Irving D, Rebeiz JJ. Total numbers of limb motor neurones in the human lumbosacral cord and an analysis of the accuracy of various sampling procedures. J Neurol Sci 1973;20:313–327.
    OpenUrlCrossRefPubMed
  17. 17.↵
    Tsukagoshi H, Yanagisawa N, Oguchi K, Nagashima K, Murakami T. Morphometric quantification of the cervical limb motor cells in controls and in amyotrophic lateral sclerosis. J Neurol Sci 1979;41:287–297.
    OpenUrlCrossRefPubMed
  18. 18.↵
    Coggeshall RE, Lekan HA. Methods for determining numbers of cells and synapses: a case for more uniform standards of review. J Comp Neurol 1996;364:6–15.
    OpenUrlCrossRefPubMed
  19. 19.↵
    Schmitz C, Hof PR. Review: design-based stereology in neuroscience. Neuroscience 2005;130:813–831.
    OpenUrlCrossRefPubMed
  20. 20.↵
    Stephens B, Guiloff RJ, Navarrete R, Newman P, Nikhar N, Lewis P. Widespread loss of neuronal populations in the spinal ventral horn in sporadic motor neuron disease: a morphometric study. J Neurol Sci 2006;244:41–58.
    OpenUrlCrossRefPubMed
  21. 21.↵
    Kawamura Y, Dyck PJ, Shimono M, Okazaki H, Tateishi J, Doi H. Morphometric comparison of the vulnerability of peripheral motor and sensory neurons in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 1981;40:667–675.
    OpenUrlCrossRefPubMed
  22. 22.↵
    Terao S, Sobue G, Hashizume Y, et al. Disease specific patterns of neuronal loss in the spinal ventral horn in amyotrophic lateral sclerosis, multiple system atrophy and X-linked recessive bulbospinal neuronopathy, with special reference to the loss of small neurons in the intermediate zone. J Neurol 1994;241:196–203.
    OpenUrlCrossRefPubMed
  23. 23.↵
    Abercrombie M. Estimation of nuclear population from microtome sections. Anat Rec 1946;94:239–247.
  24. 24.
    Offord K, Ohta M, Oenning RF, Dyck PJ. Method of morphometric evaluation of spinal and autonomic ganglia. J Neurol Sci 1974;22:65–71.
    OpenUrlPubMed
  25. 25.
    Tomlinson BE, Irving D. The numbers of limb motor neurons in the human lumbosacral cord throughout life. J Neurol Sci 1977;34:213–219.
    OpenUrlCrossRefPubMed
  26. 26.
    Yuan H, Goto N, Akita H, et al. Morphometric evaluation of the human cervical motoneurons in the aging process. Okajimas Folia Anat Jpn 2000;77:1–4.
    OpenUrlPubMed
  27. 27.↵
    Brownell B, Oppenheimer DR, Hughes JT. The central nervous system in motor neurone disease. J Neurol Neurosurg Psychiat 1970;33:338–357.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    Martin LJ. Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol 1999;58:459–471.
    OpenUrlCrossRefPubMed
  29. 29.
    Martin LJ, Price AC, Kaiser A, et al. Mechanisms for neuronal degeneration in amyotrophic lateral sclerosis and in models of motor neuron death (review). Int J Mol Med 2000;5:3–13.
    OpenUrlPubMed
  30. 30.
    Parent A. Carpenter's human neuroanatomy. 9th ed. Baltimore: Williams & Wilkins, 1996.
  31. 31.
    Elliott HC. Studies on the motor cells of the spinal cord: III. Position and extent of lesions in the nuclear pattern of convalescent and chronic poliomyelitis patients Am J Path 1945;21:87–97.
    OpenUrlPubMed
  32. 32.
    Sharrard WJ. The distribution of the permanent paralysis in the lower limb in poliomyelitis: a clinical and pathological study. J Bone Joint Surg Br 1955;37-B:540–558.
    OpenUrlPubMed
  33. 33.
    Sharrard WJ. Muscle paralysis in poliomyelitis. Br J Surg 1957;44:471–480.
    OpenUrlPubMed
  34. 34.
    Kawamura Y, Okazaki H, O'Brien PC, Dyck PJ. Lumbar motoneurons of man: I. number and diameter histogram of alpha and gamma axons of ventral root. J Neuropathol Exp Neurol 1977;36:853–860.
    OpenUrlPubMed
  35. 35.
    Schoenen J, Faull RLM. Spinal cord: cytoarchitectural, dendroarchitectural, and myeloarchitectural organization, Chapter 2. In: Paxinos G, ed. Human nervous system. San Diego, Academic Press, 1990.
  36. 36.↵
    Swash M, Leader M, Brown A, Swettenham KW. Focal loss of anterior horn cells in the cervical cord in motor neuron disease. Brain 1986;109 (pt 5):939–952.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    Kiernan JA, Hudson AJ. Changes in shapes of surviving motor neurons in amyotrophic lateral sclerosis. Brain 1993;116:203–215.
    OpenUrlAbstract/FREE Full Text
  38. 38.
    Mizusawa H, Hirano A, Shintaku M. Involvement of small neurons in anterior horn of the spinal cord in amyotrophic lateral sclerosis. Neurol Med (Tokyo) 1987;27:331–336.
    OpenUrl
  39. 39.
    Oyanagi K, Ikuta F, Horikawa Y. Evidence for sequential degeneration of the neurons in the intermediate zone of the spinal cord in amyotrophic lateral sclerosis: a topographic and quantitative investigation. Acta Neuropathol 1989;77:343–349.
    OpenUrlCrossRefPubMed
  40. 40.↵
    Parhad IM, Clark AW, Barron KD, Staunton SB. Diaphragmatic paralysis in motor neuron disease: report of two cases and a review of the literature. Neurology 1978;28:18–22.
    OpenUrlAbstract/FREE Full Text
  41. 41.
    de Carvalho M, Matias T, Coelho F, Evangelista T, Pinto A, Luis ML. Motor neuron disease presenting with respiratory failure. J Neurol Sci 1996;139 (suppl):117–122.
    OpenUrlPubMed
  42. 42.
    Chen R, Grand'Maison F, Strong MJ, Ramsay DA, Bolton CF. Motor neuron disease presenting as acute respiratory failure: a clinical and pathological study. J Neurol Neurosurg Psychiatry 1996;60:455–458.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    Hayashi H, Kato S, Kawada A. Amyotrophic lateral sclerosis patients living beyond respiratory failure. J Neurol Sci 1991;105:73–78.
    OpenUrlCrossRefPubMed
  44. 44.
    Braak H, Braak E. The pyramidal cells of Betz within the cingulate and precentral gigantopyramidal field in the human brain: a Golgi and pigmentarchitectonic study. Cell Tissue Res 1976;172:103–119.
    OpenUrlPubMed
  45. 45.
    Scheibel ME, Scheibel AB. The dendritic structure of the human Betz cell. In: Brazier MAB, Pets H, eds. Architectonics of the cerebral cortex. New York: Raven Press, 1978:43–56.
  46. 46.
    Meyer G. Forms and spatial arrangement of neurons in the primary motor cortex of man. J Comp Neurol 1987;262:402–428.
    OpenUrlCrossRefPubMed
  47. 47.↵
    Emmert-Buck MR, Bonner RF, Smith PD, et al. Laser capture microdissection. Science 1996;274:998–1001.
    OpenUrlAbstract/FREE Full Text
  48. 48.
    Eberwine J. Amplification of mRNA populations using aRNA generated from immobilized oligo(dT)-T7 primed cDNA. Biotechniques 1996;20:584–591.
    OpenUrlPubMed
  49. 49.
    Brown PO, Botstein D. Exploring the new world of the genome with DNA microarrays. Nat Genet 1999;21 (suppl):33–37.
    OpenUrlCrossRefPubMed
  50. 50.
    Jiang Y-M, Yamamoto M, Koyayashi Y, et al. Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Ann Neurol 2005;57:236–251.
    OpenUrlCrossRefPubMed
  51. 51.
    Perrin FE, Boisset G, Docquier M, et al. No widespread induction of cell death genes occurs in pure motorneurons in an amyotrophic lateral sclerosis mouse model. Hum Mol Genet 2005;14:3309–3320.
    OpenUrlAbstract/FREE Full Text
  52. 52.
    Ravits J, Laurie P, Stone B. Amyotrophic lateral sclerosis microgenomics. Phys Med Rehabil Clin N Am 2005;16:909–924.
    OpenUrlPubMed

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
Advertisement

Related Articles

  • Focality of upper and lower motor neuron degeneration at the clinical onset of ALS

Topics Discussed

  • All Spinal Cord
  • All Neuromuscular Disease
  • Anterior nerve cell disease
  • Amyotrophic lateral sclerosis

Alert Me

  • Alert me when eletters are published
Neurology: 96 (14)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise